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Available online 6 July 2016Leber's hereditary optic neuropathy (LHON) is a disease that leads to blindness. Gene therapy has been investi-
gated with some success, and could lead to important advancements in treating LHON. This was a prospective,
open-label trial involving 9 LHON patients at Tongji Hospital, Wuhan, China, from August 2011 to December
2015. The purpose of this study was to evaluate the long-term outcomes of gene therapy for LHON. Nine LHON
patients voluntarily received an intravitreal injection of rAAV2-ND4. Systemic examinations and visual function
tests were performed during the 36-month follow-up period to determine the safety and efﬁcacy of this gene
therapy. Based on successful experiments in an animalmodel of LHON, 1 subject also received an rAAV2-ND4 in-
jection in the second eye 12months after gene therapywas administered in theﬁrst eye. Recovery of visual acuity
was deﬁned as the primary outcome of this study. Changes in the visual ﬁeld, visual evoked potential (VEP), op-
tical coherence tomographyﬁndings, liver and kidney function, and antibodies against AAV2were deﬁned as sec-
ondary endpoints. Eight patients (Patients 2–9) received unilateral gene therapy and visual function
improvement was observed in both treated eyes (Patients 4, 6, 7, and 8) and untreated eyes (Patients 2, 3, 4, 6
and 8). Visual regression ﬂuctuations, deﬁned as changes in visual acuity greater than or equal to 0.3 logMAR,
were observed in Patients 2 and 9. Age at disease onset, disease duration, and the amount of remaining optic
nerve ﬁbers did not have a signiﬁcant effect on the visual function improvement. The visual ﬁeld and pattern re-
versal VEP also improved. The patient (Patient 1) who received gene therapy in both eyes had improved visual
acuity in the injected eye after the ﬁrst treatment. Unfortunately, visual acuity in this eye decreased 3 months
after he received gene therapy in the second eye. Animal experiments suggested that ND4 expression remains
stable in the contralateral eye after intravitreal injections. No serious safety problem was observed in the 3-
year follow-up of the 9 participants enrolled in this virus-based gene therapy. Meanwhile, our results support
the use of intravitreal rAAV2-ND4 as an aggressive maneuver in our clinical trial. Further study in additional pa-
tients and in these 9 subjects is needed to better understand the effects of rAAV2-ND4 gene therapy on LHONand
to increase the applications of this technique.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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. This is an open access article underLeber's hereditary optic neuropathy (LHON) is one of themost com-
mon causes of blindness in young adults. Unfortunately, there is cur-
rently no effective treatment. The most common point mutation that
leads to the development of LHON is the mitochondrial DNA 11778 G-
to-A point mutation (Mackey et al., 1996). In China, the G11778A
point mutation is present in 90% of LHON patients (Cui et al., 2013).
Therefore, we selected this mutation as the target for gene therapy.
After a series of successful animal experiments (Shi et al., 2012; Pei et
al., 2013; Gao et al., 2013), a total of 9 patients were administered an in-
travitreal injection of rAAV2-ND4 (recombinant adeno-associated virus
carrying theNADH–ubiquinone oxidoreductase subunit 4 gene) in 2011the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Fundus photography obtained before and after the intravitreal injection of rAAV2-ND4 (n= 8 patients). A representative 30° fundus photograph showing the disc and macula of
injected and uninjected eyes before (A) and at 3 months (B), 6 months (C), 12 months (D), 24 months (E), and 36 months (F) after intravitreal injection. The retinal structure appears
normal in all photographs with no apparent abnormalities.
259S. Yang et al. / EBioMedicine 10 (2016) 258–268and 2012. Early therapy outcomes for these patients have been previ-
ously reported (Wan et al., 2016), but the patients were onlymonitored
for 9 months in that study.
After examining the effects of unilateral intravitreal rAAV2-ND4 in-
jection on the injected eye, we noticed some effects of the gene therapy
in the uninjected eye. Following the completion of our animal experi-
ments, Patient 1 from the unilateral injection study chose to have
gene therapy also administered in the fellow eye. Additionally, severalTable 1
Clinical data of 9 LHON patients.
Patients Sex Age at onset of LHON Age at gene th
*1 Male 14 18
2 Male 8 10
3 Male 7 9
4 Male 13 21
5 Male 16 17
6 Female 8 9
7 Female 9 26
8 Male 13 17
9 Male 43 46
*Average 14.56 19.22
Note (*): patient 1 was the only onewho received bilateral gene therapy. *Mean has excluded th
visual acuity; IE, injected eye; UIE, uninjected eye; R, Right eye; L, Left eye.patients who had received gene therapy in only 1 eye began to show vi-
sual acuity improvements in the uninjected eye. This led us to wonder if
the gene therapy administered to 1 eye had affected the other
uninjected eye or if visual acuity improvements had resulted from spon-
taneous recovery.
Here, we report the long-term (36 months) clinical outcomes of the
9 patients who received gene therapy for LHON. Patient 1, who received
gene therapy in both eyes, is examined and described separately. Theerapy
LogMAR BCVA before gene
therapy
LogMAR BCVA 36 months
after gene therapy
IE UIE IE UIE
2.0 (R) 2.0 (L) 1.7 (R) 1.7 (L)
1.7 (R) 0.9 (L) 1.5 (R) 0.5 (L)
1.2 (L) 1.0 (R) 1.2 (L) 0.6 (R)
2.0 (L) 1.1 (R) 1.0 (L) 0.8 (R)
2.3 (R) 2.3 (L) 2.3 (R) 2.3 (L)
1.1 (R) 1.0 (L) 0.1 (R) 0.4 (L)
1.2 (L) 0.9 (R) 0.9 (L) 0.7 (R)
1.4 (L) 1.7 (R) 1.1 (L) 1.2 (R)
2.0 (R) 2.0 (L) 2.0 (R) 2.0 (L)
1.61 1.36 1.26 1.06
e patient 1. LogMAR, logarithm of theminimumangle of resolution; BCVA, best-corrected
Table 2
LogMAR vision acuity of injected and uninjected eyes of Case 2 to Case 9.
Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9
I U I U I U I U I U I U I U I U
Presurgery 1.7 0.9 1.2 1 2 1.1 2.3 2.3 1.1 1 1.2 0.9 1.7 1.4 2 2
3 months postsurgery 1.7 0.9 1.1 1 1.1 1 2.3 2.3 0.9 0.6 0.9 0.9 1.4 1.4 1.7 1.7
6 months postsurgery 1.4 0.9 1 1 1.1 1 2.3 2.3 0.5 0.5 0.9 0.7 1.2 1.2 1.7 1.7
12 months postsurgery 1.7 0.6 1.1 0.6 1 0.9 2.3 2.3 0.2 0.2 0.9 0.8 1.4 1.4 2 2
24 months postsurgery 1.2 0.7 1.2 0.8 1.2 0.9 2.3 2.3 0.1 0.4 1 0.8 1.4 1.5 2 2
36 months postsurger 1.5 0.5 1.2 0.6 1 0.8 2.3 2.3 0.1 0.4 0.9 0.7 1.1 1.2 2 2
I, injected; U, uninjected.
260 S. Yang et al. / EBioMedicine 10 (2016) 258–268clinical results of the other 8 patients who received unilateral therapy
are reported together.
1. Methods
1.1. Recombinant adeno-associated virus
Construction of a vector containing the target gene is the key in gene
therapy. However, theND4gene is found inmitochondrial DNA, and ex-
ogenous gene transfection is not suitable for the mutation of mitochon-
drial DNA. Instead, the mitochondrial DNA sequence of ND4 was
modiﬁed to a nuclear DNA sequence, which makes the translation of
ND4 protein consistent with the normal translation of the protein inFig. 2. Improvement in logMAR visual acuity from baseline after the intravitreal injection of
uninjected eyes at 3, 6, 12, 24, and 36 months after the intravitreal injection of rAAV2-ND
uninjected eyes of Patients 2, 3, 4, 6, and 9. However, visual acuity decreased in some patie
uninjected eyes improved in all 8 patients. Mean logMAR BCVA in the injected eyes of all 8
0.33 ± 0.41, 0.35 ± 0.39, and 0.39 ± 0.43 at 3, 6, 12, 24, and 36 months, respectively. Ove
uninjected eyes in these same 8 patients improved by 0.10 ± 0.16, 0.16 ± 0.18, 0.23 ± 0.28, 0the mitochondria. We constructed recombinant adenovirus 2-ND4 by
inserting amitochondrial targeting sequence (MTS). The original vector
was produced and puriﬁed at Beijing FivePlus Molecular Medicine
Institute Co. Ltd. (Beijing, China). The recombinant plasmid was exam-
ined by restriction enzyme digestion and named pAAV2neo-COX10-
ND4-COX103′ UTR.
1.2. Patients and the molecular analysis
Nine patientswere enrolled in this study. Theywere all diagnosed by
a polymerase chain reaction (PCR)-based test using an ampliﬁcation-re-
fractory mutation system to detect the presence or absence of 3 nucleo-
tide substitutions known to cause LHON (3460 G N A, 11,778 G N A, andrAAV2-ND4 (n = 8 patients). Visual acuity improvements from baseline in injected and
4. Visual acuity improved in the injected eyes of Patients 2, 4, 6, 7, 8, and 9 and in the
nts until 36 months after gene therapy, but the mean visual acuity of the injected and
patients who received unilateral gene therapy improved by 0.26 ± 0.29, 0.40 ± 0.29,
rall, patients had the best BCVA 6 months after treatment. Mean logMAR BCVA of the
.15 ± 0.21, and 0.26 ± 0.21 at 3, 6, 12, 24, and 36 months, respectively.
Table 3
Comparison of BCVA changes according to disease duration.
BCVA (logMAR) change from baseline
to 36 months
IE mean change
(logMAR)
UIE mean change
(logMAR)
Patients with ≤2 y duration (n= 4) −0.30 logMAR −0.35 logMAR
Patients with N2 y duration (n= 4*) −0.40 logMAR −0.25 logMAR
P 0.65 0.47
Note (*): Excludes patient 1 who received bilateral gene therapy.
LogMAR, logarithm of the minimum angle of resolution; BCVA, best-corrected visual acu-
ity; IE, injected eye; UIE, uninjected eye.
Table 4
Comparison of mean age at onset, disease duration, and RNFL according to therapeutic
outcome.
BCVA (logMAR) change from
baseline to 36 months (Injected
eye)*
BCVA change ≥0.3
logMAR (n= 4)
BCVA change b0.3
logMAR (n= 4) p
Mean age at onset (y) 10.75 ± 1.32 18.50 ± 8.41 0.88
Mean duration (y) 7.50 ± 3.48 2.00 ± 0.41 0.19
Mean RNFL (pre) (μm) 50.38 ± 4.90 44.25 ± 2.42 0.39
Mean RNFL (post) (μm) 46.13 ± 2.79 46.25 ± 6.01 1.00
Note (*): Excludes patient 1 who received bilateral gene therapy.
LogMAR, logarithm of the minimum angle of resolution; BCVA, best-corrected visual acu-
ity; RNFL, thickness of the retinal nerve ﬁber layer; pre, pre-treatment; post, post-
treatment.
261S. Yang et al. / EBioMedicine 10 (2016) 258–26814,484 T N C). The molecular genetic analyses were performed at Tongji
Hospital Genetic Diagnosis Center (Wuhan, China).
1.3. Study design and oversight
This was an open-label study on LHON patients with a conﬁrmed
G11778 A mutation.
Patients who did not experience spontaneous visual recovery
after 12 months of clinical observation were considered for enroll-
ment. The study protocol was reviewed and approved by the ethics
committee of Ezhou Central Hospital. All patients and their guard-
ians provided written informed consent to participate in the study.
This study is registered at ClinicalTrials.gov (registration number:
NCT01267422; registration date: December 2010). All study conduct
adhered to the tenets of the Declaration of Helsinki.
1.4. Intravitreal injection and dose
In this study, we selected a relatively lower dose than that used
for congenital amaurosis gene therapy. The dose was 5 × 109 vg/
0.05 mL for patients younger than 12 years, and 1 × 1010 vg/
0.05 mL for patients older than 12 years. Children younger than
12 years received half the dose for safety reasons. An intravitreal in-
jection of rAAV2-ND4 was administered to one eye. In order to im-
prove study safety, the eye with poorer visual acuity was chosen as
the injection eye. A similar methodology was adopted in previous
studies (Maguire et al., 2008; Bainbridge et al., 2008). If both eyes
had the same visual acuity, the right eye was designated as the injec-
tion eye. Because of safety considerations, patients underwent the
gene therapy in two batches (3 patients were injected in 2011, and
6 patients were injected in 2012). Details of the experimental design
and methodology have been previously published (Wan et al., 2016)
and are brieﬂy described below.
1.5. Ophthalmologic examinations
The primary endpoint of this study was the change in best-
corrected visual acuity (BCVA) after gene therapy administration. Vi-
sual acuity measured just prior to treatment was used as the baseline
value. The BCVA was measured using a 2.5-m standard logMAR chart
(Star KangMedical Technology Co., Ltd., Wen Zhou, China). A change
in logMAR BCVA greater than or equal to 0.3 was considered clinical-
ly signiﬁcant (Yu-Wai-Man et al., 2011; Klopstock et al., 2011). A cut-
off of 0.3 was chosen because it is equivalent to 15 letters on the Early
Treatment for Diabetic Retinopathy Study (ETDRS) chart (Beck et al.,
2003).
Visual ﬁeld testing (Humphrey ﬁeld analyzer, Carl Zeiss 740i, Carl
Zeiss, Shanghai, China) was performed using the 30–2 central
threshold test and SITA fast algorithm. The primary endpoints were
the visual ﬁeld index (VFI) and mean deviation (MD).
The Spectralis HRA + OCT system (Heidelberg Engineering,
Heidelberg, Germany) was used to measure average overall andquadrant (superior, inferior, temporal, and nasal) retinal nerve
ﬁber layer (RNFL) thicknesses.
The pattern-reversal visual evoked potential stimulus (PR-VEP;
DV-100, Shanghai Dikon Medical, Shanghai, China) was an alternat-
ing black-and-white checkerboard pattern with pattern reversal fre-
quencies of 1.0 and 100.0 Hz. The stimulation duration was 500 ms
and 100 PR-VEPs were averaged to obtain the waveforms used in
the analyses. The average screen brightness was 5 cd/m2; the pattern
had a spatial frequency of 25 ms/s and a contrast ratio of 97%. The
primary endpoint was the P100 waveform amplitude and latency.
Other ophthalmologic examinations included anterior segment
slit-lamp examination, intraocular pressure measurement
(TOPCON-CT-80 Computerized Auto Tonometer, TOPCON, Tokyo,
Japan), and fundus examination (NIDEK Autofocus Fundus Camera,
AFC-230, Nidek, Tokyo, Japan). The speciﬁcs of each type of examina-
tion have been reported previously (Wan et al., 2016). All examina-
tions were performed by the same experienced ophthalmologist or
optometrist.
1.6. Effect of gene therapy on uninjected eyes
1.6.1. Animal experiments
A total of 60 randomly selected, 4-week-old C57bl mice were
used in this study. All mice were bred and provided by the Animal
Center of Tongji Hospital (Wuhan, China). The experimental proce-
dures and approaches were similar to those of previously published
reports (Gao et al., 2013).
The mice were divided into 4 groups. Groups 1 and 2 received a
unilateral intravitreal phosphate-buffered saline (PBS) injection
and rAAV2-ND4 injection, respectively, followed by a contralateral
rAAV2-ND4 intravitreal injection in both groups 1 month later.
Groups 3 and 4 received a unilateral intravitreal PBS injection and
rAAV2-ND4 injection, respectively, followed by a contralateral intra-
vitreal rAAV2-ND4 injection in both groups 3 months later. All intra-
vitreal injections of rAAV2-ND4 were 5 μL (1 × 1011 μg/mL) in
volume.
The mice were sacriﬁced 1 month after the second intravitreal in-
jection and the retinas of all mice were isolated. Western blotting
was used to evaluate the levels of ND4 expression. Blood samples
collected from the heart were used in an enzyme-linked immunosor-
bent assay (ELISA) to determine AAV2 and AAV2 antibody concen-
trations. All experimental methods have already been described in
our previous reports (Gao et al., 2013;Wan et al., 2016). ND4 expres-
sion and concentrations of AAV2 and AAV2 antibody were compared
between Groups 1 and 2 and between Groups 3 and 4 using paired t-
tests.
1.6.2. Bilateral Gene therapy (patient 1)
Because Patient 1 experienced a large improvement in visual acu-
ity after the ﬁrst treatment, gene therapy treatment of the contralat-
eral eye was strongly requested. As the safety of the therapy had
Table 5
Ophthalmologic examination results of injected eyes of 8 patients before and 36 months after intravitreal injection.
P100 amplitudes(uV)
RNFL thickness
(average) MD of visual ﬁeld (dB) VFI of visual ﬁeld (dB)
Patient Eye Before After Before After Before After Before After
2 Right 86.1 189 48.5 45.75 – −21.83 – 28%
3 Left 303 265 48 62 −19.47 −15.53 42% 54%
4 Left 1090 1270 43.25 42.25 −30.02 −25.18 8% 21%
5 Right 2320 227 38.5 32.75 −33.01 −33.82 2% 1%
6 Right 152 6620 61.25 48.25 −34.92 −14.66 0% 60%
7 Left 146 2980 56 53 −32.41 −21.30 3% 32%
8 Right 763 2050 41 41 −26.45 −29.49 16% 8%
9 Left 618 916 42 44.5 −29.36 −28.44 9% 8%
Average 684.76 1814.6 46.19 45.69 −29.38 −23.78 11% 27%
P100 amplitudes: amplitudes P100 values increase means the visual function improvement; RNFL: retinal nerve ﬁber layer; MD: mean deviation, value close to 0 considered as normal;
VFI: visual ﬁeld index, value close to 100% considered as normal.
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we performed gene therapy on the fellow eye, which was approved
by the hospital's Ethics Committee. Patient 1 thus received gene
therapy in both eyes, and the 2 eyes were injected 12 months apart
using the same methods.
One, 3, and 6 months after the second injection, the patient
underwent thorough systemic and ophthalmologic examinations,
including physical examinations with routine blood, urine, liver, kid-
ney, and immune function tests. All laboratory analyses were per-
formed by the Laboratory Department of Tongji Hospital. Tests for
human T lymphocyte subsets CD3+, CD3+/CD4+, and CD3+/
CD8+ were conducted by the Central Laboratory of Tongji Hospital.
The third part of the physical examination was a neutralizing an-
tibody assay performed using ﬂow cytometry. Serum concentrations
of ND4, AAV, and interferon (IFN)-γ were measured via ELISA. For
the detailed methodology, please refer to our previous publication
(Wan et al., 2016).
The patient was closely monitored for 36 months following treat-
ment of the fellow eye.
1.7. Statistical analyses
Because of the small number of samples in our study, we adopted
previously used protocols (Maguire et al., 2008; Bainbridge et al.,
2008) regarding BCVA analysis for small sample sizes. The outcomes
of visual acuity for efﬁcacy were descriptive in nature and deﬁned as
any improvement in visual function rather than using statistical
methods. Using a non-parametric test (Mann–Whitney test), weTable 6
Ophthalmologic examination results of uninjected eyes of 8 patients before and 36 months aft
P100 amplitudes(uV)
Mean RNFL th
(um)
Patient Eye Before After Before
2 Left 347 234 54.75
3 Right 158 364 50.75
4 Right 849 230 46
5 Left 456 1530 43.5
6 Left 113 768 81
7 Right 291 944 42
8 Left 681 2420 39
9 Right 512 406 44.5
Average 425.88 862 50.19
P100 amplitudes: amplitudes P100 values increase means the visual function improvement; R
VFI: visual ﬁeld index, value close to 100% considered as normal.compared the BCVA changes between patients with a disease dura-
tion ≥2 years (n = 4) and b2 years (n = 4). We also compared the
mean age at onset, duration, and RNFL between the patients who ex-
perienced an improvement after the therapy (BCVA change ≥0.3
logMAR [n= 4]) and those who did not (BCVA change b0.3 logMAR
[n= 4]). In the animal studies, data were statistically analyzed with
the independent two-sample t-test. All values are presented as the
mean ± standard deviation. Statistical signiﬁcance was deﬁned as
p b 0.05.
2. Results
2.1. Safety evaluation and adverse events
Ocular adverse events, including cataracts, retinal detachment,
and endophthalmitis were not observed in any patient during the
36-month follow-up period. No retinal (Fig. 1) or other ocular tissue
damage was detected. Additionally, systemic examinations did not
reveal any abnormal change during the 36-month observation peri-
od. Systemic immunity examination results have been reported pre-
viously (Wan et al., 2016). None of the patients had any obvious
immune abnormalities or events.
2.2. Best-corrected visual acuity
Compared with baseline values, the BCVA improved in both the
injected and uninjected eyes in Patients 4, 6, 7, and 8 over the 36-
month follow-up period. The logMAR BCVA of only the uninjecteder intravitreal injection.
ickness
MD of visual ﬁeld (dB) VFI of visual ﬁeld (dB)
After Before After Before After
53 – −15.93 – 47%
42.75 −23.51 −16.33 24% 51%
46.75 −25.81 −21.22 18% 27%
36 −32.42 −33.67 3% 1%
54.25 −31.71 −9.31 9% 74%
42 −32.9 −28.54 4% 17%
43.25 −26.87 −28.93 13% 11%
47.5 −27.69 −26.53 13% 11%
45.69 −28.70 −22.56 12% 30%
NFL: retinal nerve ﬁber layer; MD: mean deviation, value close to 0 considered as normal;
Fig. 3. The visualﬁeld index (VFI), mean defect (MD), and pattern-reversal visual evokedpotential P100waveform in the injected and uninjected eyes of 8 patientswho receivedunilateral
gene therapy. The mean VFI (A) and MD (B) values of the injected and uninjected eyes before and 3, 6, 12, 24, and 36 months after intravitreal injection. Five patients had VFI and MD
improvements after treatment, but Patient 5 had no improvement. Error bars represent one standard deviation. The latency (C) and amplitude (D) of the P100 waveform in the
injected and uninjected eyes of the 8 patients who received unilateral gene therapy are shown. After gene therapy, P100 latency decreased and P100 amplitude increased in both the
injected and uninjected eyes within 6 months. This indicated an improvement in optic nerve function after gene therapy. Error bars represent one standard deviation. Mean VFI in the
8 patients who received unilateral gene therapy was 11 ± 0.15%, 28 ± 0.23%, 23 ± 0.22%, 18 ± 0.23%, 28 ± 0.18%, and 27 ± 0.22% before and 3, 6, 12, 24, and 36 months after
treatment, respectively. The mean VFIs of the uninjected eyes were 12 ± 0.07%, 29 ± 0.25%, 27 ± 0.29%, 20 ± 0.21%, 34 ± 0.28%, and 30 ± 0.25% before and 3, 6, 12, 24, and
36 months after treatment, respectively (Tables 3 and 4, Fig. 3A, B).
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eyes in Patients 2 and 3 were improved at 3 and 6months after treat-
ment compared to baseline. However, visual acuity began to de-
crease after 6 months. In contrast, BCVA in the uninjected eye
increased for 12 months after treatment and improvements were
maintained for 36 months. In Patient 9, bilateral BCVA improved ini-
tially, but decreased back to baseline after 12months. The visual acu-
ity of Patient 5 did not change signiﬁcantly during the 36-month
follow-up period (Tables 1 and 2, Fig. 2).
At 36 months post-injection, in patients with a disease duration
b2 years, an improvement of 0.3 logMAR was observed in the treated
eye and 0.35 logMAR in the untreated eye. In patientswith a disease du-
ration ≥2 years, an improvement of 0.4 logMAR was observed in the
treated eye and 0.25 logMAR in the untreated eye. There was no signif-
icant difference between these two groups (Table 3). There was no sig-
niﬁcant difference in the mean age at onset, duration, and RNFL
between the patients who experienced an improvement after the ther-
apy (BCVA change ≥0.3 logMAR [n= 4]) and those who did not (BCVA
change b0.3 logMAR [n= 4]) (Table 4).2.3. Visual ﬁeld
The visual ﬁeld (VF) improved simultaneously with visual acu-
ity. The VFIs in the injected and uninjected eyes were signiﬁcantly
better 36 months after treatment than at baseline in 5 patients (Pa-
tients 2, 3, 4, 6, and 7; Tables 5 and 6, Fig. 3A, B). Patient 2 refused VF
testing because of poor central visual acuity, but agreed to it
12 months after receiving gene therapy when visual acuity had im-
proved. The results showed that in the injected and uninjected eyes,
the VFI gradually increased, MD decreased, and VF improved. The
injected and uninjected eyes of Patients 3, 4, 8, and 9 had maximalVF improvements between 3 and 6 months after treatment, which
decreased thereafter. VF parameters improved progressively in Pa-
tients 6 and 7.
2.4. Visual evoked potentials
Visual evoked potentials (VEPs) in the 8 patients who received
unilateral intravitreal rAAV2-ND4 showed a signiﬁcant decrease in
P100 latency for 6 months after treatment, which suggested an im-
provement in optic nerve function, but returned to baseline levels
thereafter. Additionally, gene therapy increased the mean P100 am-
plitude in the injected eye from 684.76 ± 749.00 nV before treat-
ment to 1814.60 ± 2176.95 nV 36 months after treatment, but this
change was not statistically signiﬁcant (p = 0.250). The uninjected
eye also showed an increase in amplitude from 425.88 ± 252.56 nV
before treatment to 862 ± 768.94 nV after 36 months (Tables 5
and 6; Fig. 3C,D), but this change was also not statistically signiﬁcant
(p = 0.145). These changes, even though not signiﬁcant, suggest
limited optic nerve function improvement in both eyes, particularly
between 6 and 12 months after gene therapy.
2.5. Optical coherence tomography
Compared with other examination methods, optical coherence
tomography (OCT) measurements remained the most stable over
time. The retinal nerve ﬁber layer (RNFL) thickness in the injected
eyes did not change signiﬁcantly over the 36-month follow-up peri-
od. However, RNFL thicknesses in the uninjected eyes were signiﬁ-
cantly lower at 24 months after treatment than at baseline over the
entire retina and in each quadrant (superior, inferior, temporal,
and nasal; Tables 5 and 6, Fig. 4).
Fig. 4.Optical coherence tomography (OCT)measurements of retinal nerve ﬁber layer (RNFL) thicknesses in 8 patients who received unilateral gene therapy. A. Temporal RNFL thickness.
B. Inferior RNFL thickness. C. Superior RNFL thickness. D. Nasal RNFL thickness. E. Mean RNFL thickness. Average RNFL thicknesses before and 3, 6, 12, 24, and 36 months after treatment
were 47.31 ± 7.87, 46.78 ± 7.54, 48.47 ± 7.79, 46.46 ± 7.79, 43.13 ± 6.07, and 46.19 ± 8.67 μm, respectively. RNFL thicknesses of the uninjected eyes before and 3, 6, 12, 24, and
36 months after treatment were 50.19 ± 13.40, 47.97 ± 9.70, 48.19 ± 8.78, 48.08 ± 8.11, 45.25 ± 7.69, and 45.69 ± 6.01 μm, respectively. Speciﬁc measurements revealed a
decreasing trend in RNFL thickness over time. There were no signiﬁcant changes in RNFL thickness in the injected eyes over time (baseline: 47.31 ± 7.87 μm; at 36 months: 46.19 ±
8.67 μm, p=0.691). However, RNFL thickness in the uninjected eyes began to decline 24months after treatment (baseline: 50.19±13.40 μm; at 36months: 45.69±6.01 μm, p=0.245).
Fig. 5. Effects of gene therapy on the uninjected eyes of mice. A–B. The retinal ND4 protein level, measured using Western blot analysis, after injection of the second eye. There was no
signiﬁcant difference between Groups 1 and 2 (p = 0.22) or between Groups 3 and 4 (p = 0.78). C. Serum AAV2 concentration as measured using ELISA. There was no signiﬁcant
difference between Groups 1 and 2 (p = 0.86) or between Groups 3 and 4 (p = 0.51). D. Serum AAV2 antibody concentration as measured using ELISA. There was no signiﬁcant
difference between Groups 1 and 2 (p= 0.20) or between Groups 3 and 4 (p= 0.20). Error bars represent one standard deviation.
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Fig. 6. Clinical anti-AAV2-neutralizing antibody assay results following gene therapy administration in the fellow eye and fundus photography of patient 1 in both eyes 12months apart. A.
The percentage of green ﬂuorescent protein (GFP) expression inhibition (1:20). B. The percentage of GFP expression inhibition (1:60, 1:180, 1:540, and 1:1620). Three months after
receiving gene therapy, GFP expression inhibition increased when a 1:20 serum concentration was compared with serum-free medium. The inhibition of GFP expression returned to
pre-treatment levels 6 months after gene therapy. Photographs of the right (C) and left (D) fundi are shown. The photographs were taken 3, 6, and 12 months after the administration
of an intravitreal rAAV2-ND4 injection in the left eye. At 12 months, an intravitreal rAAV2-ND4 injection was also administered in the right eye. Photographs were also taken at 3, 6,
12, 24, and 36 months after treatment of the right eye. No apparent retinal abnormalities were identiﬁed.
Fig. 7. Improvement in logMAR visual acuity and changes in visual ﬁeld parameters in a
patient who received gene therapy in both eyes 12 months apart (Patient 1). A. Visual
acuity improved from baseline in the ﬁrst eye following gene therapy in that eye, but
decreased 6 months after gene therapy in the second eye. B. Serial visual ﬁeld index
(VFI) measurements showed that bilateral VFI decreased after the second eye received
gene therapy. C. Mean defect (MD) changes showed that bilateral MD worsened after
gene therapy administration in the second eye, indicating greater visual ﬁeld damage.
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2.6.1. Animal experiment results
Our animal experiments indicated that successive bilateral intravit-
real injections of rAAV-ND4 resulted in the long-term, relatively stable
expression of retinal ND4 in the second eye injected. Serum concentra-
tions of AAV2 and the AAV2 antibody were not abnormal at any time
point examined (Fig. 5).
2.7. Bilateral gene therapy (patient 1)
2.7.1. Systemic ﬁndings
All of Patient 1's blood, urine, liver, kidney, and immune function
tests were normal. The measured CD3+/CD4+ and CD3+/CD8+
values were also normal. However, the AAV2-neutralizing antibody
assay results differed between baseline and at 3months after treatment.
In Patient 1 before and at 3 months after treatment, the AAV2-neutral-
izing antibody assay showed a difference between the 1:20 serum
AAV2 and serum-free AAV2 concentrations. However, in Patient 1 at 1
and 6 months after treatment, the results of the neutralizing antibody
assay were not different between the 1:20 serum AAV2 and serum-
free AAV2 concentrations (Fig. 6A, B).
The optical densities of AAV2 before and at 1, 3, and 6 months after
treatment were 0.64, 0.75, 0.34, and 0.39, respectively. The optical den-
sities of ND4 before and at 1, 3, and 6months after treatmentwere 1.17,
1.19, 1.26, and 1.38, respectively. The optical densities of IFN-γ before
and at 1, 3, and 6 months after treatment were 1.58, 1.42, 1.56, and
1.70, respectively.
2.7.2. Ophthalmologic ﬁndings
Color fundus photography did not reveal any serious complications,
and the retinas and optic nerves in both eyes showed no signiﬁcant
changes from baseline (Fig. 6C,D). The maximum visual acuity in the
injected eye occurred 6months after treatment. One year after adminis-
tering gene therapy in the left eye, the right eye was administered with
gene therapy using the same methods. Three months later, logMAR
BCVA in the left eye decreased by 0.6 (from 1.1 to 1.7). Twelve months
later, logMAR BCVA in the right eye also began to decrease. Fortunately,
logMAR BCVA stabilized at 24 months and was 1.7 at 36 months, a 0.3
improvement over baseline (1.7 vs. 2.0, Fig. 7A).
Visual ﬁeld testing results showed similar trends as those observed
for visual acuity. After gene therapy was administered in the left eye
(ﬁrst eye), the bilateral VFI and MD both improved. However, after
Fig. 8. Retinal nerve ﬁber layer thickness (RNFL) and visual evoked potentials (VEPs) after bilateral administration of gene therapy (Patient 1). Injections were administered 12 months
apart. A. The RNFL thickness did not change in either eye during the 48-month observation period. B. The amplitude of the VEP P100 component decreased in both eyes following the
administration of gene therapy in the second eye. C. The VEP latency increased after the administration of gene therapy in the second eye. Both VEP changes are indicative of reduced
optic nerve function.
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VFI andMDdeteriorated (Fig. 7B, C). Additionally, OCT revealed that the
RNFL thickness remained stable and unchanged (Fig. 8A).
An examination of PR-VEPs revealed ﬂuctuations in P100 latency
and amplitude during the follow-up period. Twelve months after gene
therapy was administered in the ﬁrst eye, P100 latency was lower
than at baseline, and the amplitude was greater than at baseline.
These results suggest an improvement in optic nerve function. In con-
trast, 36 months after gene therapy was administered in the second
eye, P100 latency was longer than at baseline, and the amplitude was
lower than at baseline. This suggested a deterioration in optic nerve
function (Fig. 8B,C).
3. Discussion
In 2008, gene therapy for Leber's congenital amaurosiswas adminis-
tered for the ﬁrst time (Maguire et al., 2008; Bainbridge et al., 2008).
Gene therapy offers newhope for the treatment of numerous hereditary
ocular diseases and is extremely promising for treating LHON
(Cwerman-Thibault et al., 2014; Meyerson et al., 2015). We previously
reported results obtained 9 months after treating LHON patients with
an intravitreal injection of rAAV2-ND4 (Wan et al., 2016). Feuer et al.
also reported short-term (3–6 months) preliminary results of 5 LHON
patients treated with gene therapy (Feuer et al., 2016).
Therewere 4 patients (Patients 2, 3, 5, and 9)with no signiﬁcant im-
provement in visual acuity 36 months after gene therapy (b0.3
logMAR). However, it should be stressed that N2 years after therapy ad-
ministration, the visual acuities of Patients 2 and 9 increased by N0.3
logMAR and were maintained for a certain period. No patient demon-
strated a more serious decline in visual acuity from baseline. This ﬁnd-
ing further supports the safety of gene therapy with the AAV vector.
Regarding the timing of the gene therapy, patients underwent it after
an LHON clinical history of 1 year (Patients 5 and 6), 2 years (Patients
2 and 3), 3 years (Patient 9), 4 years (Patients 1 and 8), 8 years (Patient
4), and 17 years (Patient 7). In the cases where the therapy wasineffective, RNFL thicknesses ranged from 42 to 48.5 μm before treat-
ment and the duration of the LHON-associated visual acuity decrease
ranged between 2 and 3 years. These patients did not have any identiﬁ-
able common characteristics (Tables 3 and 4).
The VEP ﬁndings suggest that gene therapy can improve optic nerve
function in LHONpatients. The RNFL thicknesses in the injected eyes did
not change, but those in uninjected eyes decreased from baseline to
24 months after gene therapy administration. Previous studies have
shown that RNFL thickness continuously declines in LHON patients
(Barboni et al., 2012; Zhang et al., 2014). Therefore, our results may in-
dicate that gene therapy provides better RNFL protection for the
injected eye, but does not have protective effects in the uninjected eye
24 months after gene therapy. However, the number of participants in
our studywas small and the difference in proportions is only suggestive
and not deﬁnitive.
Patient 1 was the only patient who received bilateral treatment, so
we only reported our clinical observations. After the second eye (right
eye) received gene therapy, visual acuity decreased and VF defect
severity increased in the ﬁrst eye (left eye) for unknown reasons.
These changes could have been a coincidence or could have been caused
by a humoral immune response to AAV2 after gene therapy was
administered in the ﬁrst eye (Bainbridge et al., 2015; Tseng and
Agbandje-McKenna, 2014). However, systemic examinations prior to
administering gene therapy in the second eye showed normal humoral
immune responses. Because we cannot know for certain whyVF and vi-
sual acuity changes occurred in the ﬁrst eye, further investigation is
needed. For now, we do not recommend that gene therapy be per-
formed in the fellow eyes of patients with LHON.
It is worth noting that in the 3-year LHON gene therapy follow-up,
we found 2 unexpected phenomena. First, patients had visual acuity im-
provements over baseline after treatment, but some patients had BCVA
ﬂuctuations during the 3-year follow-up period. This was particularly
evident in Patients 2 and 9. Second, visual acuity of the contralateral
eye appeared to improve in some patients. The results of a previous
study by Feuer et al. (2016) are consistent with those found here.
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gene therapy, but this measure is somewhat subjective. An improve-
ment in logMAR visual acuity was deﬁned as an improvement of 0.3
or more. This deﬁnition minimizes the inﬂuence of subjective factors
and changes in vision greater than or equal to 0.3 logMAR during the
36-month follow-up period were also deﬁned as relative visual ﬂuctua-
tions. Based on this standard, visual regression ﬂuctuations only oc-
curred in Patients 2 and 9 and were not obvious in other patients.
Visual acuity ﬂuctuations may have been related to protein expression
stability after transfection with ND4, other persistent disease factors,
and/or patient-speciﬁc factors. Regarding the second point, according
to the 0.3 logMAR standard, Patients 2, 3, 4, and 6 demonstrated visual
acuity improvements in uninjected eyes. The following two reasons
may explain this phenomenon: spontaneous visual recovery and inﬂu-
ence of the contralateral eye. Despite the fact that 4–33% of LHON pa-
tients with the G11778 A mutation have spontaneous visual recovery
(Lam et al., 2014), these patients had an LHONonset history (visual acu-
ity decline) of N12months prior to the gene therapy clinical trial. In ad-
dition, we excluded some patients who had shown spontaneous visual
recovery before the ﬁnal gene therapy to reduce the effect of these fac-
tors on our study. Feuer et al. (2016) also suggested that spontaneous
visual recoverywas unlikely to be responsible for visual acuity improve-
ments following gene therapy (Feuer et al., 2016).
The effect of spontaneous visual recovery was further ruled out by
our comparative analysis of visual recovery times in patients who re-
ceived gene therapy and those who had a spontaneous visual recovery
(Supplementary material, Fig. S1). Some striking differences were
noted. Visual acuity mainly improved between 3 and 6 months after
gene therapy in the injected eye and between 3 and 12 months in the
uninjected eye. In contrast, the spontaneous visual recovery time was
widely variable and ranged between 1 h and 72 months from the
onset of vision loss (Fig. S2). Theseﬁndings suggest that spontaneous vi-
sual recovery occurs at random, but visual recovery following an intra-
vitreal injection of rAAV2-ND4 occurs within a ﬁxed time frame. It
should be noted that this comparative analysis had some unavoidable
limitations, including the possible introduction of biases resulting
from the study population race and sample size, testing time,
physician's behavioral differences, and other uncontrolled variables. In
addition, the sample size was small and patients who had spontaneous
visual recovery may have failed to seek timely treatment. These factors
would impact the general applicability of our comparative analysis re-
sults. However, improvements in the uninjected eyes never occurred
before improvements in the injected eyes. Visual acuity improvements
in both injected and uninjected eyes occurred within 6months after in-
jection. All these facts reduce the likelihood that a spontaneous visual
recovery resulted in visual acuity improvements following gene
therapy.
The mechanism by which gene therapy affected the contralateral
eye was investigated by Yang et al. (2015). In animal experiments, a
ﬂuorescent gold tracer was used to verify the link between the eyes
(Fig. S3). Their results suggested that some physical communication be-
tween the eyes may have occurred via the optic chiasm (Yang et al.,
2015). Luo et al. (2013) and Pernet et al. (2013) showed that a few
regenerating nerve axons crossed the optic chiasm into the contralateral
optic nerve and grew toward the contralateral retina. These studies also
suggest the possibility of direct communication between the optic
nerves. At the same time, this might play a certain role in exploring
the unknown ﬁeld of binocular optic nerves. The visual recovery curve
of Patient 1 was particularly useful for determining the timing of drug
action because both eyes received treatment.
In conclusion, our long-term (3-year) results suggested that in-
travitreal injection of rAAV2-ND4 for LHON is a safe and promising
treatment, as afﬁrmed in a small sample of clinical trials. Treatment
efﬁcacy also suggests treatment feasibility. Additional enrollment
and follow-up is underway and is expected to be completed in com-
ing years.Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.07.002.
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